[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100384927":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":60,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"patients with SPA",null,"100 SPA patients",[13,14],"Biological: Faecal sampling","Biological: Blood sampling",{"label":16,"type":10,"description":17,"interventionNames":18},"Healthy subjets","200 healthy subjets in control group",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"patients with RA","100 RA patients",[13,14],[24,29],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"BIOLOGICAL","Faecal sampling","Faecal sampling at baseline",[16,20,9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Blood sampling","Blood sampling at baseline",[16,20,9],[34],{"name":35,"affiliation":36,"role":37},"Maxime BREBAN, MD, PhD","Service de Rhumatologie, Hôpital Ambroise Paré, APHP","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","+ 33 1 49 09 56 72","maxime.breban@aphp.fr",[44],{"facility":45,"status":46,"city":47,"state":10,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Service de Rhumatologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris","RECRUITING","Boulogne-Billancourt","92100","France","FR",{"type":52,"coordinates":53},"Point",[54,55],2.24128,48.83545,{"lat":55,"lon":54},[58],{"name":35,"role":40,"phone":59,"phoneExt":10,"email":42},"+33 1 49 09 56 72",{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100384927","characterisation-of-intestinal-microbiota-of-patients-with-spondyloarthritis-or-rheumatoid-arthritis-100384927",false,"NCT04292067","Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis","MICROBIART","Inclusion Criteria:\n\nPatients:\n\n* Patient ⩾ 18 years;\n* Diagnosed as spondyloarthritis (SpA) according ASAS classification, or rheumatoid polyarthritis according ACR\u002FEULAR;\n* Affiliated to a social security scheme;\n* Have signed the written informed consent form.\n\nHealthy control subjects:\n\n* Adult women and men;\n* Subjet free of chronic pathology;\n* Affiliated to a social security scheme;\n* Have signed the written informed consent form.\n\nExclusion Criteria:\n\nPatients:\n\n* Patients unable to understand the proposed study and\u002For sign a informed consent form;\n* Pregnant women or breast feeding women;\n* Patient ⩾ 18 years;\n* Patients under guardianship or curatorship;\n* Have taken antibiotic 1 month prior to inclusion or digestive coloscopy 6 months prior inclusion;\n* Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome;\n* Foreign patients under french AME scheme;\n* Patients had have participated in the prior study Microbiart.\n\nHealthy control subjects:\n\n* Subjects unable to understand the proposed study and\u002For sign a informed consent form;\n* Pregnant women or breast feeding women;\n* Subjects \\\u003C 18 years;\n* Subjects under guardianship or curatorship;\n* Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome;\n* Refusal of subjects to participate to the study;\n* Foreign patients under french AME scheme;\n* Subjects had have participated in the prior study Microbiart.",true,"ALL","18 Years",{"count":73,"type":74},400,"ESTIMATED","OBSERVATIONAL","The primary objective of the study aims to compare the biodiversity of intestinal microbiota between spondylarthritis (SPA) or rheumatoid arthritis (RA) patients and healthy volunteers, by microbiota DNA sequencing in order to further and respond the prior results, which suggested that there is a specific dysbiosis for each of the 2 diseases. A comparative analysis will allow to identify the biomarkers of the specific bacteria.",[78,79],"Spondyloarthritis","Rheumatoid Arthritis",[78,79,81],"Microbiota","2025-06-11",{"date":84,"type":85},"2025-06-15","ACTUAL",{"date":87,"type":85},"2020-11-23",{"date":89,"type":74},"2026-11",{"name":5,"class":6},1]